Key Points:

• Five offerings were listed for pricing on October 22, 2026, across healthcare, artificial intelligence, biotechnology and nanotechnology-related businesses, reflecting a varied pipeline of U.S. market activity.
• Davion Healthcare, Emerging Markets AI Mag 3 ETF, Interpace Biosciences and Forge Nano Holdings were among the names scheduled, but the calendar does not disclose final offering prices, deal sizes or investor demand.
• The broader weekly calendar showed pricing activity on four consecutive weekdays, making final pricing outcomes and subsequent trading performance more informative than the number of scheduled transactions alone.

October 22 Pricing Calendar Shows Activity Across Several Sectors

The U.S. IPO calendar listed five offerings for October 22, 2026, with expected pricing events spanning healthcare, an artificial intelligence-focused exchange-traded fund, biotechnology and nanotechnology. The mix offers a snapshot of the range of securities reaching the market, although the calendar alone does not establish that each transaction was completed or attracted strong demand. With no offering prices, proceeds, valuations or subscription figures provided, the key measure of market strength will be whether the scheduled transactions price as expected and proceed to trading.

Five Scheduled Offerings Reflect a Diverse Issuer Mix

Davion Healthcare Plc Ordinary Shares (DAVI) were listed for Nasdaq pricing on October 22, alongside the Emerging Markets AI Mag 3 ETF (EMAG). The calendar also included Interpace Biosciences, Inc. Common Stock (IDXG), Forge Nano Holdings Inc. Common Stock (NANO) and Forge Nano Holdings Inc. Warrants (NANOW). All five entries showed the same expected date and U.S. dollar currency.

The list combines operating-company securities with an ETF and warrants, which have different investment characteristics. An ETF listing does not carry the same issuer-level financial profile as a conventional corporate IPO, while warrants provide exposure under specific contractual terms rather than the same ownership rights as common stock. Treating all five entries as equivalent IPOs would therefore overstate the comparability of the transactions.

Forge Nano’s Common Stock and Warrants Require Separate Attention

Forge Nano Holdings appeared twice on the calendar, through common stock and warrants. These entries represent distinct securities, not necessarily two separate operating-company listings. The distinction matters when assessing the number of transactions taking place: a calendar count can include multiple instruments associated with the same issuer.

The supplied calendar does not specify the warrant terms, the number of securities offered, the proposed price, or the relationship between the two listings. Without those details, the potential proceeds and implied valuation cannot be calculated reliably. Investors assessing the offering would need the applicable prospectus or official filings to understand the terms and the extent to which the securities differ in risk and potential return.

Weekly Activity Builds, but Pricing Outcomes Remain the Key Signal

The calendar covering October 18–24 showed no pricing entries for Sunday or Saturday, while Monday, October 19, had four, Tuesday, October 20, had three, Wednesday, October 21, had nine, Thursday, October 22, had five and Friday, October 23, had two scheduled pricing events. This pattern indicates a concentrated midweek schedule, followed by fewer expected events toward the end of the week.

However, scheduled activity is not a direct measure of market demand. Pricing below an indicated range, delays, withdrawals or weak post-listing trading can signal investor caution even when the calendar appears busy. Conversely, transactions that price on schedule and maintain stable aftermarket performance would offer stronger evidence that investors are willing to commit capital to new listings.

What the IPO Market Is Watching Next

The next indicators are the confirmed pricing and trading outcomes for the October 22 offerings, followed by the two events scheduled for October 23. Final offer prices, proceeds, issuer valuations and early share performance will help establish whether the calendar’s activity translates into completed transactions. Until those details are confirmed, the schedule provides evidence of planned issuance, but not enough to conclude that U.S. IPO demand is strengthening or weakening.